Targeted Therapy in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung malignancies and encompasses histological subtypes such as adenocarcinoma, squamous cell carcinoma and large cell carcinoma. The identification of oncogenic driver mutations in genes encoding receptor tyrosine kinases, notably epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and ROS1, has revolutionised treatment by enabling targeted inhibition of aberrant signalling pathways. First-generation EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib demonstrate high response rates in patients harbouring activating EGFR mutations, while second- and third-generation TKIs have been developed to overcome common resistance alterations including the T790M and C797S mutations. Parallel advances target ALK and ROS1 rearrangements, with selective inhibitors yielding improved progression-free survival. More recently, therapies directed against BRAF V600E, RET fusions and MET exon 14 skipping have broadened the therapeutic landscape. Despite initial efficacy, the emergence of acquired resistance driven by secondary mutations, bypass pathway activation or phenotypic transformation underscores the dynamic evolution of NSCLC under selective pressure. Integrative approaches combining next-generation sequencing, liquid biopsy and functional assays are now informing precision treatment algorithms, while combination strategies targeting multiple oncogenic pathways promise to delay resistance onset and extend duration of clinical benefit.

Research from Nature Portfolio

Recent integrative genomics studies have employed whole-genome sequencing of thousands of tumours to catalogue the spectrum of actionable mutations in NSCLC, demonstrating variable incidence of EGFR, ALK and other driver alterations and correlating pangenomic profiles with treatment outcomes. Circulating tumour DNA analysis through advanced CAPP-Seq methodology has delineated the heterogeneity of resistance to third-generation EGFR inhibitors, uncovering concurrent mechanisms such as MET amplification, PIK3CA mutations and novel EGFR kinase domain substitutions, and validating ctDNA as a non-invasive biomarker for real-time monitoring. Investigations into histological transformation have identified complete loss of retinoblastoma protein in NSCLC cases transitioning to small-cell lung cancer under EGFR TKI pressure, elucidating a novel mechanism driving phenotypic change and highlighting potential sensitivity to BCL2 inhibition in transformed subclones.

Targeted Therapy in Non-Small Cell Lung Cancer publication trend

The graph below shows the total number of articles in targeted therapy in non-small cell lung cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Oncogenic driver mutation: A genomic alteration that confers growth advantage and underpins tumour development.

Tyrosine kinase inhibitor (TKI): A small molecule that blocks kinase activity of receptors driving oncogenic signalling.

Circulating tumour DNA (ctDNA): Fragments of tumour-derived DNA in blood used for non-invasive genomic profiling.

Acquired resistance: The emergence of alterations that diminish therapeutic efficacy after initial response.

Histological transformation: A change in tumour phenotype, such as from NSCLC to small-cell lung cancer, under treatment pressure.

Pangenomic analysis: Comprehensive evaluation of the entire set of genomic alterations within a tumour.

References

1. Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme. Nature Medicine (2024).
2. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. PLOS Medicine (2005).
3. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. British Journal of Cancer (2019).
4. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications (2016).
5. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature Communications (2015).
6. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduction and Targeted Therapy (2021).